Document series
Trial abstracts — page 29
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 29 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SEMAX-RU-COGNITIVE-REGIONAL-JPprogramme record | Semax | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SEMAX-RU-STROKE-ELDERLYprogramme record | Semax | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SEMAX-RU-STROKE-OLEprogramme record | Semax | — | Reported | Single-arm open-label | — | — | Very low |
| SERM-DIAGNOSTIC-DDIprogramme record | Sermorelin | Phase 1 | Reported | Randomised crossover | — | — | Very low |
| SERM-DIAGNOSTIC-RENAL-IMPprogramme record | Sermorelin | Phase 1 | Reported | Phase 1 ascending dose | — | — | Very low |
| SYNCHRONIZE-1-ADHERENCEprogramme record | Survodutide | Phase 3 | Ongoing | Observational | — | — | Very low |
| SYNCHRONIZE-1-BIOMARKERprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-1-ELDERLYprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-1-OLEprogramme record | Survodutide | Phase 3 | Ongoing | Single-arm open-label | — | — | Very low |
| SYNCHRONIZE-2-REGIONAL-CNprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-2-REGIONAL-JPprogramme record | Survodutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| SYNCHRONIZE-CVOT-PKprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| SYNCHRONIZE-CVOT-RENAL-IMPprogramme record | Survodutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| THYMALIN-RU-1-ADHERENCEprogramme record | Thymalin | — | Reported | Observational | — | — | Very low |
| THYMALIN-RU-1-ELDERLYprogramme record | Thymalin | — | Reported | Randomised, double-blind, placebo-controlled | — | — | Very low |
| THYMALIN-RU-1-OLEprogramme record | Thymalin | — | Reported | Single-arm open-label | — | — | Very low |
| TRIUMPH-1-DDIprogramme record | Retatrutide | Phase 1 | Ongoing | Randomised crossover | — | — | Very low |
| TRIUMPH-1-PKprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-1-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Ongoing | Phase 1 ascending dose | — | — | Very low |
| TRIUMPH-2-BODY-COMPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-2-QOLprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-2-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-2-REGIONAL-JPprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
| TRIUMPH-3-BIOMARKERprogramme record | Retatrutide | Phase 3 | Ongoing | Randomised, double-blind, placebo-controlled | — | — | Very low |
page 29 of 30